People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

If not administered properly, the GLP-1 medication can cause nausea, abdominal pain, and cramps, possibly leading to dehydration. The doses are normally taken a week apart, so not waiting long enough ...

Health experts say popular weight-loss drugs like Ozempic and Wegovy are safe, but the FDA warns counterfeits are becoming more widespread.

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Long-Term Pick. In this article, we will summarize ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Compared to another common class of kidney medications, called DPP4is, GLP1-RA medications did better in helping slow the progression of kidney disease, keeping kidney disease patients out of the ...

GLP-1 is a hormone made naturally in the gut. It plays a big role in managing blood sugar and appetite while releasing ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

CagriSema combines the GLP-1 receptor agonist (GLP-1RA) semaglutide, used in blockbuster weight-loss drug Wegovy, with dual ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...